Iron-Busting drug shows promise in slowing devastating ALS
NCT ID NCT03293069
Summary
This study tested whether deferiprone, a drug that removes excess iron from the body, could slow the progression of amyotrophic lateral sclerosis (ALS). Researchers enrolled 372 people with early-stage ALS and randomly assigned them to receive either deferiprone or a placebo for 12 months. The goal was to see if reducing iron buildup in the brain could protect nerve cells and help patients maintain function and live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aphm Hopital La Timone
Marseille, France
-
C H U Dupuytren Limoges
Limoges, France
-
Chr Angers
Angers, France
-
Chru Brest
Brest, France
-
Chu Cote de Nacre - Caen
Caen, France
-
Chu Toulouse
Toulouse, 31300, France
-
Chu de Bordeaux - Talence
Talence, France
-
Chu de Clermont-Ferrand
Clermont-Ferrand, France
-
Chu de Nancy
Nancy, France
-
Chu de Nice Hopital Pasteur
Nice, France
-
Chu de Tours
Tours, France
-
Hopital Pierre Wertheimer - Hcl - Bron
Bron, France
-
Hopital de Hautepierre
Strasbourg, 67091, France
-
Hu Pitie Salpetriere Aphp
Paris, 75013, France
-
Hôpital Roger Salengro, CHU
Lille, 59000, France
Conditions
Explore the condition pages connected to this study.